A Study of Pyridostigmine in Postural Tachycardia Syndrome

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT00409435
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Postural Tachycardia Syndrome

Eligibility Criteria

Sex
ALL
Age
15 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • pyridostigmine — DRUG
    one 180 mg capsule per day for 3 days
  • Placebo — DRUG
    one capsule per day for 3 days

Study Details

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Key Dates

Start date
Oct 31, 2006
Status verified
Mar 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: pyridostigmine
    Active study drug
  • Placebo Comparator: Placebo
    Control

Primary Outcome Measure

Change in orthostatic symptoms using Composite Autonomic Symptom Scale (COMPASS) change [ Time Frame: 3 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Toni Gehrking
[email protected]
507-284-0336
Wolfgang Singer, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies